WHO flags funding gaps in prevention, treatment of TB

Share on WhatsAppMore current affairs

Society & Social JusticeGS 2PrelimsMains

WHO flags funding gaps in prevention, treatment of TB The WHO Global Tuberculosis Report 2026 shows that about 86% of TB spending in 2025 came from domestic sources....

Key facts for Prelims

  • Which of the following approaches best reflects an integrated strategy for achieving TB elimination?

    • (a) Focusing exclusively on expanding hospital infrastructure.
    • (b) Replacing public health programmes with private healthcare delivery.
    • (c) Combining early diagnosis, preventive treatment, nutritional support, research and community participation.
    • (d) Restricting TB control measures to countries with the highest disease burden.

    Answer: b)

WHO flags funding gaps in prevention, treatment of TB

The WHO Global Tuberculosis Report 2026 shows that about 86% of TB spending in 2025 came from domestic sources. International donor funding fell, and research funding is far below target. The South-East Asia Region carries about a third of the global burden. The report raises a central question for global health: can countries end TB by 2030 (SDG 3.3) when financing is uneven and donor support is shrinking?

Key Facts

·      Domestic share: around 86% of TB spending in 2025 came from domestic sources.

·      Concentration: Brazil, China, India, Russia and South Africa (BRICS) accounted for $3.7 billion (65%) of the $5.63 billion domestic funding in low- and middle-income countries (LMICs).

·                  Need versus supply: $22 billion a year is needed for prevention, diagnosis, treatment and care to meet the 2023 UN High-Level Meeting targets by 2027.

·      Donor decline: international donor funding fell 14%, from $1.1 billion (2024) to $0.94 billion (2025). It had been stable at $1.1-1.3 billion a year during 2015-2024.

·      Research gap: TB research funding was $1.2 billion in 2023, against a target of $5 billion a year.

·      Burden: over 80% of cases and deaths are in LMICs. South-East Asia Region (SEAR): 3.6 million new cases in 2025 and 400,000 deaths, about 34-35% of the global total.

·      Data note: the article gives both 35% and 34% for SEAR’s share of cases, so use “about a third” in answers.

Static Dimensions

·      TB: an airborne disease caused by Mycobacterium tuberculosis. It is curable, and preventable with TB preventive treatment. Drug-resistant forms (MDR/RR-TB) need longer, costlier regimens.

·      Global targets: SDG 3.3 (end the TB epidemic by 2030), WHO End TB Strategy (90% fewer cases and 95% fewer deaths by 2035 versus 2015), and UN High-Level Meeting 2023 targets for treatment coverage, preventive therapy, vaccines, financing ($22 billion) and research ($5 billion).

·      India’s programme: National TB Elimination Programme (NTEP) with the goal of ending TB by 2025, ahead of the SDG date. Key schemes:

o   Ni-kshay Poshan Yojana: direct benefit transfer for nutrition to patients.

o   Ni-kshay Mitra: community and donor support for patients.

o   Pradhan Mantri TB Mukt Bharat Abhiyaan and the 100-day intensified campaign.

o   Ni-kshay portal for case notification; new diagnostics (CBNAAT, TrueNat) and shorter drug-resistant TB regimens (BPaLM).

·      Funding institutions: Global Fund, Stop TB Partnership, and bilateral donors. India is now mostly self-financed for TB.

·      Social determinants: undernutrition, poverty, diabetes, tobacco, alcohol, HIV and crowded housing raise TB risk. Ayushman Bharat and nutrition programmes link to this.

Analysis

·      Domestic financing is the backbone: with 86% from domestic sources, national budgets decide progress. But spending is concentrated in five larger economies, leaving low-income countries dependent on shrinking aid.

·      Donor retreat, widening risk: a 14% fall in aid matters most for poorer, high-burden countries with weak fiscal space. It can affect case-finding, drug supply and community programmes.

·      Gap versus ambition: domestic spending in LMICs ($5.63 billion) plus donor funds ($0.94 billion) is far below the $22 billion needed, though the figures cover different scopes and should not be added to claim an exact gap.

·      Research underinvestment: a $1.2 billion actual against a $5 billion target slows new vaccines, rapid diagnostics and shorter regimens. TB’s vaccine, BCG, protects mainly children, so adult vaccines are a major gap.

·      Regional burden: SEAR’s one-third share shows why India, Indonesia and Bangladesh matter for global elimination. Progress here shapes the world’s outcome.

·      Equity and social determinants: medical funding alone is not enough. Nutrition support, housing, tobacco and diabetes control are needed. TB is also a poverty-linked disease, so it cuts catastrophic health costs for families.

·      India’s position: India is both the largest burden country and a large domestic funder, so it can show self-financed delivery and lead South-South cooperation, while sustaining progress in notification, treatment success and drug-resistant care.

Challenges

TB

·      Declining donor funding and global aid reprioritisation.

·      Gaps in detection, treatment adherence and drug-resistant TB.

·      Undernutrition, diabetes and other risk factors.

·      Low research and vaccine funding.

·      Health-system strain, stigma and private-sector reporting gaps.

Way Forward

·      Raise public health spending and ring-fence TB funds; use pooled and innovative financing.

·      Strengthen regional cooperation in SEAR for procurement, data and research.

·      Scale up preventive treatment, active case-finding and rapid molecular diagnostics.

·      Integrate nutrition, diabetes, tobacco and HIV services with TB care.

·      Invest in domestic R&D, vaccine trials and affordable diagnostics, with public-private partnerships.

·      Engage the private sector and communities through Ni-kshay Mitra and local bodies.

Conclusion

TB elimination depends on sustained and predictable financing as much as on medicine. With donor funds falling, domestic commitment, regional cooperation and investment in research must rise together, or the 2030 goal will slip further.

Chat with us